Journal of Clinical Oncology, Vol 3, 1379-1384, Copyright © 1985 by American Society of Clinical Oncology

ARTICLES

Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin

MG Kris, RJ Gralla, RA Clark, LB Tyson, JP O'Connell, MS Wertheim and DP Kelsen

Although many trials have evaluated the severity and treatment of nausea and vomiting immediately after cisplatin administration, no studies have focused on vomiting occurring more than 24 hours after chemotherapy--delayed emesis. Two consecutive trials were undertaken to evaluate the incidence, course (trial 1), and severity (trial 2) of delayed nausea and emesis and to develop methods to study these conditions. Eighty-six patients receiving cisplatin (120 mg/m2) for the first time were entered. On the day of cisplatin treatment, all received intravenous (IV) metoclopramide (3 mg/kg X 2 doses) plus dexamethasone (20 mg IV X 1 dose) with either diphenhydramine (50 mg IV) or lorazepam (1.0 to 1.5 mg/m2). Sixty-two percent of patients experienced no vomiting during the 24 hours immediately after administration of cisplatin. Overall, 93% of studied patients experienced some degree of delayed nausea or vomiting from 24 to 120 hours after cisplatin. In trial 1, the incidence of delayed vomiting ranged from 21% to 61% and delayed nausea from 24% to 78% in 58 patients. The highest incidence of both delayed nausea and emesis occurred during the period from 48 to 72 hours after administration of cisplatin. Patients who had no emesis during the initial 24 hours after cisplatin were less likely to experience delayed emesis. The severity of delayed nausea and vomiting was evaluated in 28 patients in trial 2. The amount of delayed nausea and vomiting was assessed daily by patients using a visual analogue scale and by an observer rating. The highest nausea and vomiting scores were seen during the period from 48 to 72 hours after administration of cisplatin, with acceptable correlation between patient scores and observer ratings. Although the nausea and vomiting occurring 24 or more hours after cisplatin administration is not as severe as that seen during the initial 24 hours after administration of cisplatin in patients not receiving antiemetics, it is a common condition that merits both further study and specific treatment.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. J. Hesketh Chemotherapy-Induced Nausea and Vomiting N. Engl. J. Med., June 5, 2008; 358(23): 2482 - 2494. [Full Text] [PDF]

				G. Kumar, K. A. Hayes, and R. Clark Efficacy of a Scheduled IV Cocktail of Antiemetics for the Palliation of Nausea and Vomiting in a Hospice Population American Journal of Hospice and Palliative Medicine, June 1, 2008; 25(3): 184 - 189. [Abstract] [PDF]

				D. L. Robinson and B. A. Carr Delayed Vomiting in Children With Cancer After Receiving Moderately High or Highly Emetogenic Chemotherapy Journal of Pediatric Oncology Nursing, March 1, 2007; 24(2): 70 - 80. [Abstract] [PDF]

				M. Aapro, S. Grunberg, G. Manikhas, G Olivares, T Suarez, S. Tjulandin, L. Bertoli, F Yunus, B Morrica, F Lordick, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy Ann. Onc., September 1, 2006; 17(9): 1441 - 1449. [Abstract] [Full Text] [PDF]

				M. G. Kris, P. J. Hesketh, M. R. Somerfield, P. Feyer, R. Clark-Snow, J. M. Koeller, G. R. Morrow, L. W. Chinnery, M. J. Chesney, R. J. Gralla, et al. American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006 J. Clin. Oncol., June 20, 2006; 24(18): 2932 - 2947. [Abstract] [Full Text] [PDF]

				M. G. Kris Why Do We Need Another Antiemetic? Just Ask. J. Clin. Oncol., November 15, 2003; 21(22): 4077 - 4080. [Full Text] [PDF]

				W. C. Mertens, D. J. Higby, D. Brown, R. Parisi, J. Fitzgerald, E. M. Benjamin, and P. K. Lindenauer Improving the Care of Patients With Regard to Chemotherapy-Induced Nausea and Emesis: The Effect of Feedback to Clinicians on Adherence to Antiemetic Prescribing Guidelines J. Clin. Oncol., April 1, 2003; 21(7): 1373 - 1378. [Abstract] [Full Text] [PDF]

				R. H. Rosen Management of Chemotherapy-Induced Nausea and Vomiting Journal of Pharmacy Practice, February 1, 2002; 15(1): 32 - 41. [Abstract] [PDF]

				D. Campos, J. R. Pereira, R. R. Reinhardt, C. Carracedo, S. Poli, C. Vogel, J. Martinez-Cedillo, A. Erazo, J. Wittreich, L.-O. Eriksson, et al. Prevention of Cisplatin-Induced Emesis by the Oral Neurokinin-1 Antagonist, MK-869, in Combination With Granisetron and Dexamethasone or With Dexamethasone Alone J. Clin. Oncol., March 15, 2001; 19(6): 1759 - 1767. [Abstract] [Full Text] [PDF]

				A. Hole, A. Conway, and S. Quadir Audit of efficacy of 3 mg versus 1 mg of intravenous granisetron as antiemetic prophylaxis against acute emesis caused by cisplatin or melphalan Journal of Oncology Pharmacy Practice, December 1, 1999; 5(4): 194 - 196. [Abstract] [PDF]

				R. J. Gralla, D. Osoba, M. G. Kris, P. Kirkbride, P. J. Hesketh, L. W. Chinnery, R. Clark-Snow, D. P. Gill, S. Groshen, S. Grunberg, et al. Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines J. Clin. Oncol., September 1, 1999; 17(9): 2971 - 2971. [Full Text] [PDF]

				P. J. Hesketh Defining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice Oncologist, June 1, 1999; 4(3): 191 - 196. [Abstract] [Full Text]

				R. M. Navari and P. J. Hesketh Use of Placebos in Delayed-Emesis Studies J. Clin. Oncol., May 1, 1999; 17(5): 1644 - 1644. [Full Text] [PDF]

				R. M. Navari, R. R. Reinhardt, R. J. Gralla, M. G. Kris, P. J. Hesketh, A. Khojasteh, H. Kindler, T. H. Grote, K. Pendergrass, S. M. Grunberg, et al. Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1-Receptor Antagonist N. Engl. J. Med., January 21, 1999; 340(3): 190 - 195. [Abstract] [Full Text] [PDF]

				S. M. Grunberg and P. J. Hesketh Control of Chemotherapy-Induced Emesis N. Engl. J. Med., December 9, 1993; 329(24): 1790 - 1796. [Full Text]

				H. J. Durivage and N. L. Burnham Prevention and Management of Toxicities Associated With Antineoplastic Drugs Journal of Pharmacy Practice, January 1, 1991; 4(1): 27 - 48. [PDF]

				P. H. M. De Mulder, C. Seynaeve, J. B. Vermorken, P. A. van Liessum, S. Mols-Jevdevic, E. L. Allman, P. Beranek, and J. Verweij Ondansetron Compared with High-Dose Metoclopramide in Prophylaxis of Acute and Delayed Cisplatin-Induced Nausea and Vomiting: A Multicenter, Randomized, Double-Blind, Crossover Study Ann Intern Med, December 1, 1990; 113(11): 834 - 840. [Abstract] [PDF]